Better Targeting, Delivery of RNAi Therapies
Forgoing the Comforts of Small Molecules and Antibodies, Some Drug Developers Are Setting Their Sights on RNAi-Based Therapeutics
Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Congress faces a January 2, 2013, deadline to deliver on $1.2 trillion in promised spending cuts over the next decade or else see that much cut across the board including from biopharma-focused federal agencies including NIH, NSF, CDC, and FDA. While CBO has estimated the cut will slice 7.8% from agency budgets, other groups have pegged the impact higher. FASEB projects it could reach the low double-digits. NIH has projected the 7.8% cut would result in 2,300 fewer grants, while an analysis last year predicted NSF would fund nearly 1,500 fewer research and education grants as a result. Partisan squabbling continues, and until the political impasse is resolved—and that’s not expected until after Election Day—the biopharma research community faces the prospect of fewer grants, fewer decisions on new drugs, and less activity overall stemming from across-the-board cuts in the budgets of federal agencies.